OT-82 resistance was related to a high expression of CD38 in ALL cells.317,318 In preclinical studies, OT-82 was well tolerated and showed no cardiac, neurological, or retinal toxicities in toxicological studies in mice and nonhuman primates.318 Currently, OT-82 is in phase 1 clinical evaluation of safety and efficacy in participants with relapsed or refractory lymphoma (clinicaltrials.gov; NCT03921879, Table 1). This evidence concerns the gene CD38 and acute lymphoblastic leukemia.